Your browser doesn't support javascript.
loading
TFE3 -Rearranged PEComa/PEComa-like Neoplasms : Report of 25 New Cases Expanding the Clinicopathologic Spectrum and Highlighting its Association With Prior Exposure to Chemotherapy.
Argani, Pedram; Gross, John M; Baraban, Ezra; Rooper, Lisa M; Chen, Suping; Lin, Ming-Tseh; Gocke, Christopher; Agaimy, Abbas; Lotan, Tamara; Suurmeijer, Albert J H; Antonescu, Cristina R.
Afiliación
  • Argani P; Departments of Pathology.
  • Gross JM; Oncology.
  • Baraban E; Departments of Pathology.
  • Rooper LM; Oncology.
  • Chen S; Departments of Pathology.
  • Lin MT; Oncology.
  • Gocke C; Urology, The Johns Hopkins Medical Institutions, Baltimore, MD.
  • Agaimy A; Departments of Pathology.
  • Lotan T; Oncology.
  • Suurmeijer AJH; Departments of Pathology.
  • Antonescu CR; Oncology.
Am J Surg Pathol ; 48(7): 777-789, 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38597260
ABSTRACT
Since their original description as a distinctive neoplastic entity, ~50 TFE3 -rearranged perivascular epithelioid cell tumors (PEComas) have been reported. We herein report 25 new TFE3 -rearranged PEComas and review the published literature to further investigate their clinicopathologic spectrum. Notably, 5 of the 25 cases were associated with a prior history of chemotherapy treatment for cancer. This is in keeping with prior reports, based mainly on small case series, with overall 11% of TFE3 -rearranged PEComas being diagnosed postchemotherapy. The median age of our cohort was 38 years. Most neoplasms demonstrated characteristic features such as nested architecture, epithelioid cytology, HMB45 positive, and muscle marker negative immunophenotype. SFPQ was the most common TFE3 fusion partner present in half of the cases, followed by ASPSCR1 and NONO genes. Four of 7 cases in our cohort with meaningful follow-up presented with or developed systemic metastasis, while over half of the reported cases either recurred locally, metastasized, or caused patient death. Follow-up for the remaining cases was limited (median 18.5 months), suggesting that the prognosis may be worse. Size, mitotic activity, and necrosis were correlated with aggressive behavior. There is little evidence that treatment with MTOR inhibitors, which are beneficial against TSC -mutated PEComas, is effective against TFE3 -rearranged PEComas only one of 6 reported cases demonstrated disease stabilization. As co-expression of melanocytic and muscle markers, a hallmark of conventional TSC -mutated PEComa is uncommon in the spectrum of TFE3 -rearranged PEComa, an alternative terminology may be more appropriate, such as " TFE3 -rearranged PEComa-like neoplasms," highlighting their distinctive morphologic features and therapeutic implications.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Reordenamiento Génico / Biomarcadores de Tumor / Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice / Neoplasias de Células Epitelioides Perivasculares Idioma: En Revista: Am J Surg Pathol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Reordenamiento Génico / Biomarcadores de Tumor / Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice / Neoplasias de Células Epitelioides Perivasculares Idioma: En Revista: Am J Surg Pathol Año: 2024 Tipo del documento: Article